Upon completion of this activity, participants should be able to: (1) Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history; (2) Select optimal first-line treatment for individual patients with advanced or metastatic RCC, considering current and emerging options, available clinical evidence, expert recommendations, and patient preferences; (3) Plan evidence-based and expert recommended therapeutic sequencing strategies for patients with RCC; (4) Manage specific disease-related complications or adverse events associated with currently approved treatments for advanced RCC; and (5) Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/RCC
- Start Date: 2024-08-30 05:00:00
- End Date: 2024-08-30 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AVEO Oncology - Amount: 0.0 - Is Kind Support: False Source: Eisai, Inc. - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Community/Population Health, Learner Knowledge, Learner/Team Competence, Learner/Team Performance, Patient Health
- Provider Ship: Directly Provided
- Registration: Open to all